Interestingly the co. that I think would benefit most, Bod Aus (BDA) is down 4c (10%) and MMJ is flat with low trading volume.
AC8 will benefit because this highlights the difference between the now-OTC CBD preparations and AC8's THC/CBD medication grade preparations which will remain prescriber only.
AC8 will increase in value, imo, as the differentiation makes the distinction clear.
Interestingly the co. that I think would benefit most, Bod Aus...
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)